The role of JAK2 inhibitors in MPNs 7 years after approval
Open Access
- 31 May 2018
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 131 (22), 2426-2435
- https://doi.org/10.1182/blood-2018-01-791491
Abstract
Myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia vera (PV), and primary myelofibrosis (MF). Phenotype-driver mutations of JAK2, CALR, and MPL genes are present in MPNs and can be variably combined with additional mutations. Driver mutations entail a constitutive activation of the JAK2/STAT pathway, the key signaling cascade in MPNs. Among JAK2 inhibitors (JAKis), ruxolitinib (RUX) has been approved for the treatment of intermediate and high-risk MF and for PV inadequately controlled by or intolerant of hydroxyurea. Other JAKis, such as fedratinib and pacritinib, proved to be useful in MF. The primary end points in MF trials were spleen volume response (SVR) and symptom response, whereas in PV trials they were hematocrit control with or without spleen response. In advanced MF, RUX achieved a long lasting SVR of >35% in ∼60% of patients, establishing a new benchmark for MF treatment. RUX efficacy in early MF is also remarkable and toxicity is mild. In PV, RUX achieved hematocrit control in ∼60% of cases and SVR in 40%. Symptom relief was evident in both conditions. In the long-term, however, many MF patients lose their SVR. Indeed, the definition of RUX failure and the design of new trials in this setting are unmet needs. Decrease of hemoglobin/platelet levels and increased infection rates are the most common side effects of RUX, and nonmelanoma skin tumors need to be monitored while on treatment. In conclusion, the introduction of JAKis raises the bar of treatment goals in MF and PV.This publication has 92 references indexed in Scilit:
- Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasmsBlood, 2013
- Mutations and prognosis in primary myelofibrosisLeukemia, 2013
- Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcomeBlood, 2012
- The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasmsHaematologica, 2010
- Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patientsHaematologica, 2010
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsBlood, 2010
- Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conferenceBlood, 2009
- Clinical relevance of JAK2 (V617F) mutant allele burdenHaematologica, 2009
- Leukemic transformation of polycythemia veraCancer, 2005